LEGAL UPDATE / 48
SAKURA Law Office | Managing Partner Kenshiro Michishita
Initial research date: 13 October 2026 | Analysis and final revision: 27 October 2026
Longevity and biohacking have developed into an unusually broad commercial proposition. At one end of the market are preventive health programmes built around nutrition, exercise, sleep and established disease-risk management. At the other are injectable compounds, cellular and extracellular-vesicle products, laboratory tests intended to estimate biological age, and experimental interventions designed to alter biological processes associated with ageing. The businesses are sometimes presented as participants in a single movement. Legally, however, they may occupy entirely different categories, with different evidence requirements, regulators, authorisations, professional obligations and routes to market. An investor or executive assessing this industry cannot begin with the commercial description of the product alone.
The central difficulty is the speed with which claims travel from scientific investigation into consumer advertising. A change in an epigenetic marker is not necessarily a clinically meaningful improvement; an association between a biological pathway and ageing is not proof that manipulating that pathway prolongs life; and permission to undertake research is not a licence to advertise a treatment as safe and effective. The U.S. National Institute on Aging's fiscal year 2026 research materials discuss the development and validation of molecular ageing clocks. Those materials are evidence of a significant research agenda, not regulatory endorsement of the accuracy or utility of every commercial biological-age test. The legal consequences arise when a company turns an exploratory finding into an assurance on which a patient, consumer or investor is expected to rely. [1]
These distinctions have immediate implications for Japanese and international businesses. A Japanese company may acquire a U.S. research platform, invest in a clinic, license a biomarker algorithm, import an investigational material, collaborate with a hospital or establish a subscription service integrating genomic and wearable data. Each arrangement entails different questions concerning the U.S. Food and Drug Administration (FDA), the Federal Trade Commission (FTC), Japan's Act on the Safety of Regenerative Medicine (ASRM), Japan's Pharmaceuticals and Medical Devices Act (PMD Act), medical advertising, privacy, product liability and corporate governance. A procedure available within one jurisdiction or research setting does not acquire lawful commercial status in another jurisdiction by translation, affiliation or contract.
This Legal Update examines the regulatory architecture as a continuous commercial decision-making process. It begins with the scientific meaning of longevity claims, proceeds to U.S. product classification and compounding, analyses Japan's amended regenerative-medicine framework, and then considers evidence-based advertising, health and genomic information, international investment, transaction documents and board oversight. Its purpose is neither to dismiss promising biomedical research nor to validate any particular treatment. It is to explain how the value of that research can be developed, financed and communicated without confusing scientific possibility, regulatory permission and proven clinical benefit. The legal analysis is current to 27 October 2026; it is not a systematic clinical-evidence review or an exhaustive survey of every U.S. state’s medical and pharmacy laws.
Executive Summary
Longevity and biohacking are commercial expressions, not self-standing categories of FDA authorisation. Product classification turns on composition, processing, intended use, administration and claims. Cell- or tissue-containing HCT/Ps must be distinguished from cell-free exosome products: the latter should not be placed automatically within the section 361 HCT/P pathway. An HCT/P qualifies for regulation solely under section 361 and the relevant Part 1271 rules only if all applicable criteria are met. Therapeutically marketed exosome products may instead engage drug and biological-product requirements. FDA warning letters communicate agency findings in identified matters; they are not judicial rulings against every regenerative-medicine technique. [4, 5, 7]
Peptides and intravenous NAD+ illustrate a different misconception. The availability of a compounding pathway under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act does not mean that a compounded preparation has completed the FDA's ordinary premarket evaluation. The legality of a particular preparation depends on the statutory exception, eligibility and quality of ingredients, intended use, relevant FDA policy and other applicable law. The FDA has separately warned of contamination risks where food-grade NAD+ is used to prepare sterile injections. This is a patient-safety finding, not recognition of a life-extension benefit. [13, 18]
Health and longevity advertising must be evaluated independently of manufacturing permissions. The FTC assesses the net impression of an advertisement and ordinarily expects competent and reliable scientific evidence, often well-controlled human clinical testing for health-related benefits. Changes in a surrogate marker do not, without more, establish that a product reduces disease or extends survival. Japan has its own intersecting restrictions under the PMD Act, the Medical Care Act, the Act against Unjustifiable Premiums and Misleading Representations and the Health Promotion Act. Translating advertising approved for a U.S. campaign is not a sufficient Japanese-law review. [24, 41, 44]
Japan’s ASRM amendments, effective 31 May 2025, brought specified nucleic-acid medical technologies within its clinical-provision framework. Plan submission, clinical research and PMD Act marketing authorisation remain distinct, and the one-year transition for pre-existing provision is not a continuing permission for new activity. U.S. testing analysis must also account for the vacatur of the 2024 LDT rule and the 2025 restoration of the regulatory text, distinguishing marketed test kits from laboratory-developed services. Health-data projects require separate HIPAA, FTC and Japanese APPI assessments. Uncommenced provisions of Japan’s 2026 APPI amendment must not be treated as present authority to reuse patient data. For investment, scientific evidence, regulatory status, commercial representations, quality controls and data rights must align with the revenue model. [32, 34, 21, 50]
1. From Longevity Research to Commercial Claims:
Healthspan, Ageing Clocks and Evidence
The first question in a longevity venture is not whether ageing represents a worthwhile field of research. It is whether the undertaking has identified with sufficient precision what is being provided, what result is promised and the evidence supporting that result. Established interventions that improve cardiovascular risk factors or support healthy activity should not be placed on the same evidentiary footing as an injectable substance purported to reverse cellular ageing. Even where both appeal to the broader objective of extending healthspan, the evidentiary bridge from mechanism to patient benefit is product-specific. An assertion that a certain biomarker has moved in a favourable direction may be accurate within its experimental context yet misleading if converted into a claim that the user has gained a measurable number of years of life.
Epigenetic clocks and other molecular markers illustrate the problem. The National Institute on Aging has described a research landscape involving numerous ageing clocks built from DNA-related, protein and other molecular information. These methods may illuminate patterns of ageing and support future clinical investigation. Their suitability for a consumer-facing determination is a separate question involving analytical validity, clinical validity and clinical utility. Predictive performance in a defined cohort does not automatically translate to an individual diagnosis; a measured response to an intervention does not automatically establish fewer illnesses, improved functioning or lower mortality. Before a company offers personalised risk predictions or sells repeated testing as evidence of rejuvenation, its medical, scientific and legal teams should identify which propositions can be substantiated and which are hypotheses requiring further testing. [1, 24]
Regulatory classification frequently begins with the intended-use evidence that the company itself creates. The words used on a website, in an influencer video, in a clinic brochure or during sales calls can be relevant to whether a product is represented as treating or preventing disease or affecting bodily structure or function. The FTC examines the overall impression a reasonable consumer takes from the advertisement, not merely a footnote disclaiming medical advice. A conspicuous claim of substantial life extension is not necessarily neutralised by a small statement that results may vary. Likewise, a clinical trial registration, patent application, academic collaboration, FDA establishment registration or regenerative-medicine development designation must not be repackaged as if it were an approval of a specific anti-ageing benefit. [7, 24]
ClinicalTrials.gov is maintained by the National Library of Medicine, not an FDA product-approval register. Trial listing does not establish governmental approval of the safety or effectiveness of a study or product. FDA establishment registration and RMAT designation are separate concepts; neither converts an investigational longevity claim into a marketing authorisation. [3, 2, 11]
There is a material distinction between discovery research, animal work, first-in-human investigation, controlled human trials and evidence adequate to support claims of clinical effectiveness. Research can justify additional investment at one stage without justifying unrestricted commercial sales at the next. Companies seeking market access must identify whether the contemplated activity is an authorised clinical study, the practice of medicine with an existing approved product, a regulated diagnostic service or the sale of a new therapeutic product. These are not interchangeable descriptions. The same product may also raise distinct questions about patient consent, advertising to prospective participants, adverse-event reporting and contract allocation across sponsor, manufacturer, investigator and treatment facility.
For boards and investors, the commercial model should therefore be divided into current lawful revenues and future contingent value. Data-analysis subscriptions, research services, physician-delivered services and a therapy requiring future approval do not share identical risk profiles or development horizons. A financing presentation that assumes near-term treatment revenues should identify the legal basis for providing the treatment and the evidence that can lawfully be communicated to customers. If the business instead depends on clinical validation and prospective approval, its contracts, fundraising milestones and governance should reflect that uncertainty. The capacity to acknowledge the difference between a promising mechanism and an approved clinical claim is not a weakness in a biotechnology investment case; it is central to its credibility.
2. FDA Regulation of Stem Cells and Exosomes:
Product Classification Beyond the Language of Wellness
Stem cells and exosomes must not be assigned automatically to the same regulatory pathway. Under 21 CFR 1271.3(d), HCT/Ps are defined by reference to products containing or consisting of human cells or tissues, with exclusions that include certain secreted or extracted human products. Cell-free exosome products therefore require a distinct classification analysis; therapeutic intended use and product characteristics may engage drug and biological-product regulation. Autologous or allogeneic source is not the same question as homologous use, which concerns performance of the same basic function in the donor and recipient. [4, 7]
For an HCT/P, section 1271.10(a) establishes cumulative criteria for regulation solely under section 361 and the relevant Part 1271 rules. Minimal manipulation and homologous use must be assessed alongside the restrictions on combination with other articles and the conditions concerning systemic effects, dependence on living-cell metabolic activity and specified autologous, blood-relative or reproductive uses. Failure to qualify may engage additional drug, biological-product or device requirements according to the product. Neither medical discretion nor administration within a clinic removes those product-law questions. [5, 6]
The FDA’s 26 May 2026 warning letter to Blue Horizon International, LLC concerned umbilical-cord-blood-derived stem-cell products and exosome products derived from Wharton’s-jelly mesenchymal stem cells. The agency identified extensive disease-treatment claims, found that the cellular products did not satisfy relevant criteria including homologous use, and identified the absence of required biologics licensure and an IND in effect. These are product- and use-specific agency findings, not a final criminal judgment or a blanket prohibition on every cell-based medical technique. [7]
The FDA's 5 May 2025 warning letter to Supreme Rejuvenation, LLC similarly addressed particular exosome-related products and the way those products were represented and marketed. Read together with the agency's broader consumer alerts on unapproved regenerative-medicine products, these documents show why marketing claims, manufacturing records, sourcing and regulatory filings must be assessed as a single evidentiary record. Patient safety is not resolved by the sophistication of the scientific terminology. Risks of infection, contamination and other serious adverse outcomes may require regulatory action even where the underlying biological research remains potentially valuable. The firm should also distinguish a regulator's warning from subsequent enforcement proceedings, a negotiated response or an adjudicated outcome; those procedural stages cannot be collapsed into a claim of final liability. [8, 9]
Historical consumer alerts must not be treated as an exhaustive account of approvals in 2026. On 18 December 2024, the FDA approved Ryoncil, an allogeneic bone-marrow-derived mesenchymal stromal cell product, for steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older. That is approval of a particular product and indication, not of general rejuvenation or life extension. Both warnings and approvals must be read with their dates and precise scope intact. [9, 10]
An investigational new drug submission and a biologics licence or other marketing authorisation serve different functions. An IND framework may allow specified clinical investigation under required controls; it does not authorise a company to sell an investigational product generally for longevity purposes. Conversely, a product already approved for a defined indication does not thereby have every proposed application approved. Physicians' lawful clinical use of approved products outside labelled indications, where permitted, does not confer upon a manufacturer a right to advertise an unapproved use or distribute a distinct unapproved product. The FDA's regenerative medicine advanced therapy, or RMAT, designation is likewise a development and review mechanism in defined circumstances, not a general commercial licence or a certification that the therapy reverses ageing. [2, 11, 12]
An IND submission should also be distinguished from an IND in effect under which investigation may lawfully proceed. Merely filing documents is not proof that all conditions for commencing a study have been satisfied. [2, 7]
In cross-border transactions, the regulatory assessment should identify the specific product used in each treatment pathway and obtain records evidencing its manufacturer, chain of custody, material processing, quality controls, clinical and commercial status, clinical protocols and adverse-event history. A U.S. medical licence held by a clinic or physician does not by itself resolve federal product-law requirements for the material administered. Equally, the presence of FDA registration information should not be taken as evidence of a particular product approval. An investor should ask whether a marketed treatment is in fact investigational, who sponsors the investigation, what consent was obtained and whether the commercial claims correspond to the precise regulatory position. These questions should be answered before valuation is based on projected patient throughput or intellectual-property licensing revenues.
Transaction documents ought to reflect these distinctions. Schedules to a research, manufacturing, licensing or acquisition agreement should identify approved products, investigational materials, research-only materials and permitted services separately. Regulatory cooperation covenants, rights to inspect quality records, disclosure of agency communications, adverse-event reporting, suspension rights and termination mechanisms should be proportionate to the actual risks. A broad warranty that the company 'complies with all health laws' does not allocate the commercial consequences of an FDA warning, an interrupted clinical study or the discovery that a supplier delivered a product whose intended use was inconsistent with its regulatory status. Responsibility should follow the actual control that each party exercises over product design, manufacture, promotion, prescribing and patient treatment.
3. Peptides, NAD+ and Dietary Supplements:
Why Compounding Is Not Product Approval
Peptide-based products and NAD+ infusions occupy a different commercial and regulatory terrain but demonstrate a recurring error in reasoning. A substance may be of research interest; a physician may consider a particular treatment; and a pharmacy may be capable of preparing an individual prescription. None of those facts establishes that the FDA has independently reviewed and approved the preparation for safety and effectiveness as a commercial drug. Federal law provides distinct statutory conditions for drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Whether a preparation falls within a relevant exception depends on the applicable requirements for the entity, ingredients, circumstances and methods of compounding, as well as state pharmacy law and other provisions of federal law. An exception from specified provisions of drug law must not be described as a general product authorisation. [13]
Section 503A ordinarily centres on compounding for an identified patient on a valid prescription, with limited anticipatory compounding subject to conditions. A registered section 503B outsourcing facility may compound without patient-specific prescriptions where the statutory conditions are met, but remains subject to current good manufacturing practice and other requirements. Bulk-substance eligibility also differs: approved-drug components, applicable compendial standards, statutory lists and shortage provisions must be examined under the relevant pathway. A nomination, an interim enforcement policy, inclusion on a final bulk-substance list and approval of a finished drug are distinct events. [13, 14]
The FDA has published information on bulk drug substances proposed for compounding that may present significant safety risks. Its materials concerning certain peptides, including BPC-157, discuss such matters as immunogenicity, peptide-related impurities and insufficient safety information for particular proposed routes of administration. The regulatory listing and nomination process must be read as it stands on the relevant date, because categories, nominations and agency consideration can change. Neither a proposal before an FDA advisory committee nor inclusion on an agency webpage can be treated without examination as a final substantive authorisation or as a categorical ban covering every form of research. A company relying on a bulk-substance supply arrangement should establish the currently applicable statutory and administrative position for the precise substance and formulation, rather than using the loose commercial designation 'research peptide' as a substitute for legal classification. [15, 14]
Current policy developments require the same discipline. BPC-157 and other substances appeared on the agenda for the FDA’s 23–24 July 2026 Pharmacy Compounding Advisory Committee meeting; an agenda is not a final regulation. The Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94), received by OIRA on 14 October 2026, was shown as pending review when checked for this article. Final issuance, operative conditions and approval of any particular product are separate questions. A pending policy must not be relied upon as present authority to supply a preparation. [16, 17]
Intravenous NAD+ highlights the separate issue of product quality. In its November 2024 notice regarding ingredients for sterile compounding, the FDA described the use of food-grade nicotinamide adenine dinucleotide in intravenous preparations and reports of severe chills, shaking, vomiting and fatigue consistent with excessive endotoxin exposure. The notice does not determine the effectiveness of NAD+ as a life-extension intervention. It explains why suitability for ingestion and suitability for sterile injection are distinct questions and why procurement, specification, testing and quality assurance have direct consequences for patient safety. The contractual chain from raw-material supplier to repackager, compounder, clinic and medical practitioner must preserve traceability and allocate responsibility for contamination, recalls, patient notifications and relevant regulatory engagement. [18]
Dietary supplements and wellness products require another classification exercise. Under U.S. law, qualified structure/function statements and prohibited disease-treatment claims are not simply stylistic alternatives. Conditions concerning substantiation, notifications and applicable disclaimers may apply, while disease-related intended-use representations can bring other regulatory requirements into play. The FTC separately tests the evidentiary basis and overall impression of advertising. A product label cannot transform a claim about preventing dementia, curing metabolic disease or extending human survival into an acceptable supplement statement merely by including a standard disclaimer. Where an app, consumer test or digital service accompanies the product, the parties must also assess whether its diagnostic or therapeutic functions engage medical-device rules. [19, 24]
A Japan-facing venture cannot import the U.S. legal label along with the substance. Japanese classification depends on composition, intended use, claims and the actual route to market. MHLW’s personal-import FAQ concerns ordinary individuals importing for their own use; it does not authorise resale or transfer to others. Importation or clinical use by a physician or medical institution is a separate, fact-specific analysis under the procedures applicable to that actor and conduct, not something resolved solely by a consumer FAQ. A history of overseas use or importation is not Japanese marketing approval. Cross-border licences should distinguish U.S. research and supply rights from what the Japanese party may lawfully manufacture, import, administer or advertise, with future regulatory permission treated as a milestone rather than a present entitlement. [53, 31, 38]
4. Japan's Regenerative-Medicine Framework:
Clinical Provision and Product Authorisation Are Separate Routes
Japan's regulatory system for regenerative medicine contains a fundamental distinction unfamiliar to some overseas investors. The Act on the Safety of Regenerative Medicine governs the safe provision of regulated regenerative-medical techniques in specified healthcare settings, including statutory procedures involving provision plans, review committees and, where applicable, the manufacture of relevant processed materials. The Pharmaceuticals and Medical Devices Act independently governs marketing authorisation and associated manufacturing and quality obligations for drugs, medical devices and regenerative medical products. The submission or publication of a regenerative-medicine provision plan by a medical institution is not an official approval that the treatment is clinically effective, nor a marketing authorisation for a manufactured product. Each assertion made to patients or commercial partners must identify the correct legal pathway. [31, 38]
The amendments effective on 31 May 2025 brought specified medical technologies using nucleic acids within the ASRM and established relevant provision and manufacturing arrangements. The principal implementation notice is dated 15 May 2025 (Iseikenhatsu 0515 No. 18), not the commencement date; notices concerning detailed provision-plan information and transitional measures are dated 30 May. The regulated material and clinical technique, statutory exclusions and interaction with investigational frameworks remain decisive. The amendment did not place every genetic test, DNA-analysis service or laboratory activity within a single clinical-provision regime. [31, 32, 33, 34]
The transition for pre-existing businesses is not an indefinite grace period. The one-year transition for qualifying nucleic-acid medical provision already taking place at commencement extended only through 30 May 2026; continued provision from 31 May 2026 requires the applicable procedures. That transition must be distinguished from the separate conditions governing manufacturing-facility applications and notifications. Diligence should establish when treatment actually began and which transitional provision was relied on, not merely whether a plan now exists. [34, 37]
Extracellular-vesicle regulation requires a separate temporal distinction. MHLW’s 30 May 2025 Q&A treats secreted substances such as exosomes and culture supernatants clearly containing no cells as outside the ASRM. Working-group material dated 8 October 2026 discusses a proposed regulatory direction for extracellular vesicles, not a comprehensive regime already in force. Being outside the ASRM does not remove applicable PMD Act product requirements, professional duties or advertising restrictions. [35, 36, 41]
A U.S. investigation conducted under an IND or at an American research hospital cannot be transferred to a Japanese clinical setting simply on the strength of its U.S. compliance file. Before a Japanese healthcare provider offers the intervention, the participants must review whether and how it falls within the ASRM, the applicable risk class, committee review, provision-plan requirements, manufacturing facility and quality controls, and any alternative or additional PMD Act or clinical-research obligations. Conversely, Japanese lawful provision of a medical technique cannot be converted into FDA marketing authorisation by a U.S. affiliate. The two countries' frameworks protect related interests but regulate different acts through different institutional procedures.
Gene-related programmes also require an independent assessment of Japan’s Cartagena Act where genetically modified organisms fall within its scope. An ASRM plan or patient consent does not replace an approval required for Type 1 use or other relevant conduct. The orders announced by MHLW and the Ministry of the Environment on 27 May 2026 illustrate that more than one regulatory framework can govern the same treatment activity. [37]
The distinction affects patient-facing arrangements as well as investment structuring. Whether an activity is investigational research, a regulated clinical trial intended to support approval, or healthcare delivery is not determined solely by whether the participant pays for treatment. Clinical research registration, ethical review, informed consent and treatment-provider responsibilities must follow the applicable framework. Informed consent should address what is known about potential benefit and what is uncertain, the proposed materials and administration, foreseeable risks, available alternatives, financial terms and responsibility for adverse-event management and use of resulting data. Consent to participate in research is not the same as proof that the participant understood every implication of a commercially promoted but incompletely validated treatment.
The PMDA's official English explanation of regenerative medical products, together with its Japanese regulatory materials and English reference translations, is particularly useful to foreign counsel. These sources clarify the distinct product approval route and the existence of approval conditions, review standards and product-specific assessments. Their availability must not encourage reliance on an outdated or explanatory English translation in preference to current Japanese legislation and notices. For international transactions, counsel should map the law at the date of proposed treatment, importation or sale, and should treat guidance, notifications and statutory obligations according to their respective legal status. [38, 39, 40]
A prudent commercial structure should therefore segregate research and development, authorised product supply, clinical services, patient acquisition and data analytics. A technology licence might permit laboratory evaluation while expressly conditioning human administration or commercial promotion on applicable approvals and institutional review. A clinic collaboration may require separate medical judgments, clinical governance and patient agreements rather than allowing a commercial distributor to dictate treatment protocols. The parties should allocate delays or refusals of regulatory permission, termination or suspension of research, costs of adverse events and post-treatment follow-up before a single integrated revenue target is promised. The result is not unnecessarily burdensome contracting; it is the legal architecture necessary to preserve the value of the scientific work.
5. Longevity Advertising and Biological-Age Testing:
Scientific Claims Under U.S. and Japanese Law
The FTC’s 2022 Health Products Compliance Guidance explains advertising substantiation under the FTC Act and related law; it is agency guidance, not a separate product-authorisation scheme. Objective health claims require competent and reliable scientific evidence before dissemination. Sound randomised and controlled human testing is ordinarily central to health-benefit claims, but the required evidence depends on the claim’s nature, strength and relevant scientific field. A study of an ingredient is not automatically a study of a combined regimen; a favourable biomarker statistic is not proof of meaningful clinical improvement. A claim of biological-age reversal must be tested against the impression actually conveyed—an algorithmic score, a validated health prediction or an assurance of longer life. [24]
Biological-age testing requires a distinction among analytical validity, clinical validity and clinical utility. Marketed in vitro diagnostic kits and tests developed and performed within laboratories should not automatically be placed on one regulatory pathway. The FDA records that the 6 May 2024 LDT final rule was vacated by a federal district court on 31 March 2025 and that the agency restored the prior regulatory text on 19 September 2025. The vacated rule’s staged implementation plan must not be described as a current compliance timetable. The actual test, intended use, supply model, governing law and agency position require individual analysis. [20, 21]
CLIA laboratory-quality oversight is also distinct from proof that a test improves health outcomes. CMS explains that CLIA does not assess clinical validity. A reproducible output, use of a certified laboratory or compliance with a particular regulatory pathway does not establish that an improved biological-age score means longer survival. Agreements with laboratories, algorithm developers and clinical customers should separate analytical performance, clinical interpretation, permitted claims and responsibility for updating the model and its evidentiary basis. [22, 23, 24]
The issue is sharpened where businesses advertise their scientific associations. University collaboration, a patent application, an investigator's credentials, a trial listing, FDA establishment registration or a development designation can all be relevant facts. None necessarily supports the broader implication that an agency has approved a commercial treatment or that a study has proved survival benefit. The FTC assesses what consumers are led to believe from the full presentation. Companies using medical advisers, celebrity endorsers or influencers should ensure that the actual communications remain within the permitted evidentiary and regulatory boundaries. Approval of a core brochure is insufficient if an affiliate adds exaggerated claims through a landing page, a social-media clip or an individual sales presentation. [2, 24]
Japan-facing advertising requires separate review of PMD Act Article 66, addressing false or exaggerated advertising, and Article 68, prohibiting advertising of specified unapproved products, alongside Medical Care Act controls on advertisements for clinical services. The representations legislation and Health Promotion Act have their own scopes, including relevant food-related health claims. MHLW’s medical-advertising materials posted following the 2026 revision explain the conditions under which certain websites may be released from the ordinary limits on advertisable matters, including prescribed information on treatment, cost and risks. Such relaxation is not permission for false or exaggerated claims and does not override separately applicable PMD Act prohibitions. Privately paid treatment is not exempt merely because public insurance does not reimburse it. [41, 42, 43, 44]
The legal review process should accompany the development of scientific claims, rather than occur after advertising campaigns have been booked. Clinical staff should define accurately what the evidence establishes; legal and compliance teams should translate that into permissible claims and required qualifications; and marketing functions should have clear controls for modifications. Contracts with agencies, clinic partners and influencers should preserve prior-review rights, rights to obtain supporting data, correction and takedown powers, auditability and rules for retaining past versions of advertisements. Patient information sheets should separately explain uncertainty and material risk. A consumer disclaimer is not a substitute for adequate informed consent, and a patient consent form does not cure misleading public advertising. Treating those documents as distinct functions reduces both regulatory exposure and subsequent disputes.
6. Health, Genetic and Wearable Data:
HIPAA, the FTC and Japanese Cross-Border Transfers
For some longevity companies the principal asset is longitudinal information about blood chemistry, DNA, medication, sleep, activity, imaging and medical history. Linking those datasets creates opportunities but also distinct legal questions for treatment, research, commercial secondary use, advertising and overseas disclosure. One document may validly record more than one consent where applicable requirements are met; the difficulty is not the number of forms but whether each purpose, recipient and foreign transfer has the required legal basis and disclosures. A broad consent clause does not supply missing permissions. Nor is a contractual assertion of anonymity sufficient without examination of identifiability, linkage and re-identification risk. [27, 45, 48]
HIPAA is not a universal U.S. health-data law applicable to every wellness business. Its primary regulatory relationships involve covered entities and business associates, as defined in the applicable rules. An independent app that collects information directly from consumers may be outside the HIPAA framework, whereas an entity processing protected health information on behalf of a covered healthcare provider may become a business associate and require corresponding arrangements. The U.S. Department of Health and Human Services explains these distinctions and discusses circumstances in which an individual selects an app to receive medical information. The precise relationship and data flow—not the word 'health' in the company's branding—determine how those rules apply. Absence of HIPAA coverage is not an affirmative conclusion that the company is unregulated. [27, 28]
The FTC's Health Breach Notification Rule provides a separate example. As amended in 2024, it addresses specified vendors of personal health records, related entities and service providers, including certain health apps and connected technologies outside HIPAA. Its applicability depends on the statutory definitions, the capability and sources of the data involved and the circumstances of an incident. Unauthorised disclosure as well as certain other unauthorised acquisitions can engage the rule. A provider should not assume that only a criminal intrusion into its servers constitutes a notifiable event: an improperly configured transmission to advertising or analytics infrastructure may require examination. Notification timelines, regulator communications, incident documentation and roles between controller, service provider and affiliated companies should be addressed before an incident occurs. Other applicable U.S. federal or state privacy rules must be considered in their own right. [25, 26]
Japanese law separately addresses special care-required personal information, including relevant medical histories and clinical records, and personal identification codes, which include specified genomic information. Genetic information does not invariably fall into one identical statutory category. Subject to statutory exceptions, acquisition of special care-required personal information and third-party provision of the corresponding personal data require consent; the ordinary opt-out disclosure mechanism is unavailable for such data. Purpose, identifying characteristics, linkage to other records and the actual conditions of any academic-research exception must be examined. A commercial analytics business cannot assume that research participation alone authorises every subsequent use. [45, 46, 47, 49]
Article 28 adds a foreign-transfer analysis. Outsourcing or an intra-group relationship does not itself disapply the rules on provision to a third party abroad. Counsel should distinguish consent-based transfers, treatment of a recognised equivalent jurisdiction, a recipient’s equivalent-measures framework and other statutory exceptions, together with the information and continuing-assurance duties applicable to the chosen route. The data contract should provide reporting, verification and suspension arrangements through which those conditions can actually be maintained. [48]
Japan’s further APPI amendments, enacted on 10 July and promulgated on 17 July 2026, include new consent-related exceptions for statistical uses and changes concerning academic research. At this article’s review date, implementation rules for the new data-use exceptions discussed here were still being prepared. The general commencement provision requires a date set by Cabinet Order within two years of promulgation, with separate commencement categories for certain provisions. An expected future exception must not be treated as current permission to acquire, disclose or use patient data for AI development. [50, 51, 52]
An acquisition data room may contain information that the seller has no authority to disclose to every bidder merely because an NDA exists. Appropriate early diligence may use aggregate information, lawful anonymisation or restricted reviews. CFIUS sensitive personal data is not synonymous with all personally identifiable information. Health-related categories have conditions concerning the relevant population, scale or business objective, while identifiable results of individual genetic tests have a distinct category; a small dataset is not automatically outside scope. Sections 800.241 and related provisions require analysis of the data, U.S. business, investor and rights acquired. CFIUS jurisdiction must be distinguished from a mandatory declaration and from any prohibition on the transaction. [29, 30]
A defensible data transaction distinguishes ownership of equipment and software from rights to collect, use, license and transfer information. Agreements should state which party may use historical records for clinical care, research validation, product development or commercial AI training; what consent and transfer mechanism supports each purpose; whether data must be deleted or returned on termination; and which entity bears responsibility for breaches, patient notices and regulatory cooperation. The quality of genomic predictions and algorithms must be evaluated alongside these rights. Projected revenue from a database whose onward use was never properly authorised may be commercially significant in a pitch deck yet legally unavailable to the acquirer.
7. Investment, M&A and Board Oversight:
Converting Biomedical Promise into Durable Enterprise Value
A longevity transaction should be analysed by revenue pathway rather than by the appeal of the underlying science. A service providing general wellness guidance, a laboratory operating a diagnostic test, a medical clinic offering a particular procedure, a manufacturer supplying ingredients, and a company developing an investigational biologic may share founders and a brand, but they have different regulators, operating permissions and potential liabilities. Investment valuation should distinguish earnings currently generated from lawful activities from contingent value dependent on clinical validation, reimbursement, manufacturing capacity or future authorisation. An investor who treats unapproved therapeutic sales as a durable earnings stream without examining their legal basis may materially overstate the value of the business.
Investment in a U.S. clinic also requires state-specific review of medical licensure, corporate operation and control of clinical judgment. The Medical Board of California, for example, explains restrictions on the corporate practice of medicine and on placing clinical and certain medical-management decisions in unlicensed hands. A management services organisation (MSO) agreement is not a safe harbour where the investor effectively controls clinical decisions. This is a California illustration, not a uniform ownership rule for all states. The target’s jurisdictions and actual allocation of decision-making authority require local review. [54]
Regulatory due diligence must join the legal assessment to the actual scientific and operational records. The buyer should seek a product-and-service classification memorandum, research protocols, clinical trial and ethics approvals where relevant, correspondence with FDA or Japanese authorities, quality and batch documentation, chain-of-custody records, adverse-event and complaint logs, advertising substantiation files, clinical and research consent forms, insurance arrangements and material third-party contracts. Records concerning peptides described as being 'for research use only' should be compared with the actual disposition and use of those products. Trial registrations should be reconciled to the way services are marketed and billed. Claims made by affiliates, distributors and influencers should be checked against the representations endorsed by the regulated manufacturer or medical provider. Patent ownership and academic collaboration arrangements likewise require attention to background intellectual property, joint development, publication rights and restrictions on sublicensing.
The investment agreement or share purchase agreement must allocate those facts and uncertainties with more precision than a generic representation of legal compliance. Relevant warranties may concern known regulatory communications, product classification, ownership and permitted use of data, material adverse events and completeness of specified clinical records. Covenants may require prompt notice of inspection findings, recalls, clinical-study suspensions, patient-safety incidents, material changes in advertising or the loss of key suppliers. Where future approval is essential to the acquisition thesis, an approval-dependent milestone, long-stop date, price mechanism or closing condition may be more appropriate than a warranty that an authority will approve the product by a fixed date. No private contract can bind a regulator to reach that outcome.
Cross-border collaborations require corresponding discipline across the entire chain of agreements. The research and development agreement should define investigational scope and publication rights; the manufacturing and supply agreement should prescribe quality, traceability and incident-response procedures; the clinical services agreement should preserve the physician's professional responsibilities; the marketing arrangement should specify permitted claims and approval processes; and the data agreement should map lawful transfer and secondary use. These contracts cannot be reviewed independently if one document promises unrestricted commercial distribution while another restricts materials to research, or if a data-processing contract allows unlimited promotional reuse contrary to the consent obtained from patients. Particular attention should be paid to procedures for suspending Japanese referrals or promotional activity if a U.S. partner receives an FDA warning letter or becomes unable to supply a compliant product.
Post-completion integration is not an administrative afterthought. Centralising databases, transferring research materials, changing treatment facilities, replacing suppliers, moving manufacturing operations or integrating U.S. and Japanese marketing teams can alter the assumptions on which compliance was assessed at signing. The board should receive reporting that separates scientific progress, patient safety, regulatory permission and commercial performance. It should be able to identify a material adverse finding, require independent review, suspend unsupported claims, provide for continuing care where necessary and adjust development plans before deficiencies escalate into serious patient harm or regulator intervention. Financial reporting and investor communications should reflect those controls rather than assume that every research milestone is a commercially permitted claim.
The opportunities in longevity research are substantial, and transnational collaboration may be indispensable to realising them. The law does not require businesses to forecast which interventions will one day meaningfully change human ageing. It requires them to state accurately what has been established today, protect the participants whose health and information are at stake, comply with the relevant paths to research and market access, and allocate the costs of uncertainty transparently. Durable enterprise value will belong to ventures capable of validating their scientific propositions while maintaining regulatory discipline, not to those that present an exciting hypothesis as an already authorised cure. For lawyers, directors and investors, the task is to construct transactions and governance arrangements that remain sound whether a promising treatment succeeds, is delayed, or fails to secure the evidence and approvals it needs.
Frequently Asked Questions
Q1. Has the FDA approved immortality, age reversal or longevity treatment as a general medical category?
No. Longevity and biohacking are not blanket FDA approval categories. The relevant product, clinical indication, regulatory status, evidence and permitted promotion must be examined individually. [2]
Q2. Does a biological-age test showing a lower age establish that a person will live longer?
No. A change in a molecular or algorithmic score does not by itself establish reduced disease incidence, longer life or improved clinical outcomes. Analytical and clinical validity and the evidence supporting any advertised benefit must be assessed separately. [1, 24]
Q3. Are all stem-cell or exosome treatments illegal in the United States?
There is no uniform answer. Assess the HCT/P definition and section 361 criteria for cell- or tissue-containing products separately from drug and biological-product requirements for therapeutic cell-free exosomes. Homologous use and autologous or allogeneic source are different questions. Approved cellular products exist, but approval of a defined indication is not approval of general life extension. [4, 5, 10]
Q4. Does ClinicalTrials.gov registration or RMAT designation authorise commercial sale?
No. Registration on ClinicalTrials.gov, maintained by the NLM, is not FDA approval. RMAT designation, FDA establishment registration and research under an IND in effect must each be distinguished from marketing authorisation. [3, 2, 11]
Q5. Does compounding a peptide such as BPC-157 mean the FDA has approved it as safe and effective?
No. The relevant section 503A or 503B conditions, ingredient eligibility, quality and use must be assessed. Neither an advisory-committee agenda nor the peptide-compounding policy received by OIRA on 14 October 2026 and pending at the review date is an established supply permission or safety approval. [13, 15, 16, 17]
Q6. Is NAD+ infusion clinically proven to prolong life?
The FDA materials reviewed here do not establish approval of NAD+ injections for life extension. The notice about unsuitable ingredients and adverse reactions concerns quality and safety; it is not, by itself, a comprehensive determination of clinical efficacy or its absence. An efficacy claim needs separate evidence corresponding to the population, preparation, administration and representation made. [18, 24]
Q7. What changed under Japan's regenerative-medicine amendments in May 2025?
Specified nucleic-acid medical technologies entered the framework on 31 May 2025. The principal implementation notice is dated 15 May, not the commencement date. The one-year transition for qualifying pre-existing provision extended through 30 May 2026; manufacturing and other transitional conditions must be assessed separately. [32, 34]
Q8. Does filing a Japanese regenerative-medicine provision plan prove government approval of effectiveness?
No. ASRM clinical-provision procedures and PMD Act marketing authorisation and efficacy review for products are separate regimes. Public-facing communications must not present one as the other. [31, 38]
Q9. May a U.S. longevity advertisement be translated and used unchanged in Japan?
Not without a separate review. Distinguish PMD Act restrictions on product advertising from Medical Care Act controls on clinical-service advertising, alongside the representations and Health Promotion Acts. Relaxation of the ordinary limits for a qualifying medical website does not authorise false or exaggerated statements or disapply separate PMD Act prohibitions. [41, 43, 44]
Q10. Do all U.S. health and longevity apps fall under HIPAA?
No. HIPAA depends principally on covered-entity and business-associate relationships. FTC health-data rules and state laws may still apply to a service outside HIPAA. [27, 25]
Q11. Can genetic and blood-test data be transferred freely to an overseas group company?
No blanket permission exists. Examine identifiability, sensitive-data status, purpose, third-party disclosure and Article 28 foreign-transfer requirements, distinguishing consent and information duties from equivalent-measures routes. Research consent or group affiliation alone does not justify commercial reuse or foreign provision, nor can an uncommenced data-use exception under the 2026 amending Act be applied early. [45, 48, 50]
Q12. What is the central legal issue in acquiring a U.S. or Japan-based longevity business?
Whether the actual source of revenue aligns with product and service classification, required authorisations, scientific evidence, quality and adverse-event records, advertising, ownership and permitted use of patient data, and the allocation of regulatory risk in the transaction documents.
About the Legal Update Series
SAKURA Law Office and Managing Partner Kenshiro Michishita publish the Legal Update series to provide primary-source-based analysis of matters affecting corporate decision-making, including corporate law, M&A, cross-border investment and disputes, financial regulation, governance, technology, intellectual property and healthcare and life sciences. The series distinguishes binding law, agency guidance, regulatory enforcement, developing research and counsel's practical recommendations, with particular attention to how those differences should influence contractual allocation, investment appraisal, risk management and dispute response. Further information concerning the firm and the author is available on SAKURA Law Office's official website and the professional profile of Managing Partner Kenshiro Michishita.
How SAKURA Law Office Can Assist
SAKURA Law Office can advise on Japanese and cross-border legal issues associated with longevity, regenerative medicine, biohacking and healthcare investment, including Japan's medical-provision and product-authorisation frameworks, advertising review, health and genomic data, licensing, research collaboration, supply and technology-transfer arrangements, regulatory due diligence and transaction structuring. Where a particular issue concerns U.S. pharmaceutical, clinical, professional or state law, advice should be coordinated as appropriate with duly qualified local counsel and relevant medical and technical advisers. Legal advisers cannot confer regulatory approval or assure the effectiveness of a proposed treatment.
Contact
SAKURA Law Office
Ark Hills South Tower 4F, 1-4-5 Roppongi, Minato-ku, Tokyo 106-0032, Japan
Managing Partner Kenshiro Michishita
Related resources: SAKURA Law Office Official Website | Profile of Managing Partner Kenshiro Michishita
Principal References
Reference numbers and destinations are identical in the Japanese and English versions. Access and status-review date: 27 October 2026. Each title is a live hyperlink. The notes distinguish legal texts, editorial compilations, guidance, historical notices, pending policy and deliberative material. English descriptions of Japanese titles are explanatory translations; consult the Japanese originals.
1. National Institute on Aging (NIH) | Fiscal Year 2026 Budget
Historical FY2026 budget and research-policy material, not approval of any individual test.
2. FDA | Understanding FDA Terms for Possible New Therapies to Prevent and Treat Diseases
Maintained official guidance; where no publication or revision date is stated, use the access date.
3. National Library of Medicine (NLM) | ClinicalTrials.gov Disclaimer
Official explanation of registration: listing is not governmental approval of safety or effectiveness.
4. eCFR | 21 CFR § 1271.3: HCT/P definitions and exclusions
Current editorial compilation of federal regulations; see, in particular, paragraphs (c) and (d).
5. eCFR | 21 CFR § 1271.10: Criteria for regulation solely under section 361
Current editorial compilation of federal regulations; cumulative criteria in paragraph (a).
6. FDA | Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use
Final guidance, July 2020; distinguish guidance from the regulations themselves.
7. FDA | Warning Letter to Blue Horizon International, LLC
26 May 2026. Agency findings in an individual matter, not a final judicial determination.
8. FDA | Warning Letter to Supreme Rejuvenation, LLC
5 May 2025. Agency findings concerning identified products and conduct.
9. FDA | Important Patient and Consumer Information About Regenerative Medicine Therapies
Safety notice dated 3 June 2021; not used as an exhaustive statement of products approved today.
10. FDA | FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-Refractory Acute Graft-Versus-Host Disease
18 December 2024. Product- and indication-specific approval announcement.
11. FDA | Regenerative Medicine Advanced Therapy Designation
Maintained official guidance; where no publication or revision date is stated, use the access date.
12. FDA | Understanding Unapproved Use of Approved Drugs “Off Label”
Maintained official guidance; where no publication or revision date is stated, use the access date.
13. FDA | FD&C Act Provisions That Apply to Human Drug Compounding
Official comparison of section 503A and section 503B conditions and exemptions.
14. FDA | Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
Official explanation bearing a 14 May 2026 update; distinguishes nominations, interim policy and the final list.
15. FDA | Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Maintained safety information; BPC-157 also appears under substances whose nominations were withdrawn.
16. FDA | 23–24 July 2026 Pharmacy Compounding Advisory Committee: Meeting Notice and Agenda
Advisory-committee meeting material; agenda inclusion is not a final rule or product approval.
17. OMB/OIRA | Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94)
Received 14 October 2026; pending review when checked on 27 October. Not treated as a finally issued policy.
18. FDA | FDA Reminds Compounders to Use Ingredients Suitable for Sterile Compounding
November 2024 notice concerning suitable ingredients, including NAD+; not an efficacy approval.
19. FDA | Structure/Function Claims
Maintained official guidance; where no publication or revision date is stated, use the access date.
20. FDA | Direct-to-Consumer Tests
Maintained official guidance; where no publication or revision date is stated, use the access date.
21. FDA | Laboratory Developed Tests
Official account of the 2024 final rule, its 31 March 2025 vacatur and the 19 September 2025 regulatory-text reversion.
22. Centers for Medicare & Medicaid Services (CMS) | Clinical Laboratory Improvement Amendments (CLIA)
Programme information bearing a 7 October 2026 update; laboratory-quality regulation.
23. CMS | CLIA Oversight of Laboratory Developed Tests: FAQs
Historical FAQ, 22 October 2013; cited only for its explanation that CLIA does not assess clinical validity, not for current FDA authority.
24. FTC | Health Products Compliance Guidance
Agency guidance published in 2022 explaining advertising substantiation under the FTC Act and related law.
25. eCFR | 16 CFR Part 318: Health Breach Notification Rule
Current editorial compilation of federal regulations, including the 2024 amendments.
26. FTC | Complying with the FTC’s Health Breach Notification Rule
Official business guidance explaining the rule following its 2024 amendments.
27. U.S. Department of Health and Human Services (HHS) | Covered Entities and Business Associates
Maintained official guidance; where no publication or revision date is stated, use the access date.
28. HHS | FAQ on HIPAA Liability When Electronic Health Information Is Transmitted to an App at an Individual’s Request
Maintained official guidance; where no publication or revision date is stated, use the access date.
29. U.S. Treasury | CFIUS FAQ: Is Personally Identifiable Information the Same as Sensitive Personal Data?
Maintained official guidance; where no publication or revision date is stated, use the access date.
30. eCFR | 31 CFR Part 800: CFIUS Regulations
Current editorial compilation; distinguish sensitive data (§800.241), TID U.S. businesses (§800.248) and mandatory declarations (§800.401).
31. MHLW | Statutes, Implementing Instruments and Notices under the Act on the Safety of Regenerative Medicine
Official collection of law and notices, including the amendments effective 31 May 2025; Japanese.
32. MHLW | Implementation Notice on the ASRM, Enforcement Order and Enforcement Regulations
15 May 2025, Iseikenhatsu 0515 No. 18; distinguish the notice date from commencement; Japanese.
33. MHLW | Detailed Information for Provision Plans for Medical Technologies Using Nucleic Acids
30 May 2025, Iseikenhatsu 0530 No. 5; issued notice; Japanese.
34. MHLW | Notice on Transitional Measures under the Amended ASRM
30 May 2025, Iseikenhatsu 0530 No. 4; separate transitions for provision and manufacturing; Japanese.
35. MHLW | Questions and Answers on the Act on the Safety of Regenerative Medicine
30 May 2025 version; in particular Q1-1-07 and Q1-1-08 on secreted material and culture supernatants; Japanese.
36. MHLW | Working-Group Material Concerning Extracellular Vesicles and Related Products
Meeting material, 8 October 2026, including proposed regulatory directions; not law already in force; Japanese.
37. MHLW / Ministry of the Environment | Announcement of Orders to Medical Institutions under the Cartagena Act
27 May 2026. Administrative measures illustrating the separate controls relevant to gene therapy; Japanese.
38. PMDA | Regulatory Materials Concerning the Review of Regenerative Medical Products
Maintained official collection; check the date and scope of each notice; Japanese.
39. PMDA | Regenerative Medical Products
Official English explanation; not a replacement for the governing Japanese legal text.
40. PMDA | English Reference Information on Approved Regenerative Medical Products and Review Reports
Official reference-material collection; verify the individual product, indication and translation date.
41. MHLW | Advertising Restrictions for Pharmaceuticals and Related Products
Official explanation reproducing relevant provisions, including PMD Act Articles 66 and 68; Japanese.
42. MHLW | Medical Advertising Guidelines and Related Materials
Official portal including materials posted following the 2026 revision; distinguish guidance and Q&A from legislation; Japanese.
43. MHLW | Questions and Answers on the Medical Advertising Guidelines
Version posted following the 2026 revision; see Q2-14, Q2-17 and Q3-26 on unapproved or off-label matters; Japanese.
44. Consumer Affairs Agency | Official Materials on False or Exaggerated Health-Food Advertising
Maintained official collection concerning the representations and Health Promotion Acts; verify each document’s version and scope; Japanese.
45. Personal Information Protection Commission (PPC) | APPI Guidelines: General Rules
Currently posted administrative guidelines; distinguish uncommenced provisions of the 2026 amending Act; Japanese.
46. PPC | Healthcare and Long-Term Care FAQ on Special Care-Required Personal Information
Maintained official guidance; where no publication or revision date is stated, use the access date.
47. PPC | FAQ Q1-24: Genome Data Handled by Academic Research Institutions
Official FAQ bearing an April 2022 update; academic research is not a blanket exemption.
48. PPC | APPI Guidelines: Provision to a Third Party in a Foreign Country
Currently posted guidance on Article 28 consent, information and equivalent-measures requirements; Japanese.
49. PPC / MHLW | Guidance on Appropriate Handling of Personal Information by Healthcare and Long-Term Care Providers
Currently posted administrative guidance; Japanese.
50. PPC | Information on the 2026 APPI Amendments
Official page recording enactment on 10 July and promulgation on 17 July 2026, and implementation preparations.
51. PPC | Promulgated Text of the Act Partially Amending the APPI and Related Acts
Promulgated 17 July 2026; commencement categories in supplementary Article 1. New data-use exceptions discussed in this article were not yet operative at the review date.
52. PPC | Future Work Following Enactment of the APPI Amendments
31 July 2026. Implementation roadmap is indicative, not a fixed commencement instrument.
53. MHLW | Questions and Answers on Personal Imports of Pharmaceuticals and Related Products
Maintained official guidance; where no publication or revision date is stated, use the access date.
54. Medical Board of California | Corporate Practice of Medicine
Official explanation of California restrictions; not presented as a uniform rule for all U.S. states.
Disclaimer
This Legal Update provides general legal and regulatory information based on public primary materials reviewed as of 27 October 2026. It neither endorses a treatment’s efficacy nor constitutes individual legal or medical advice or determines the status of a particular product, clinic, patient or investment. Scientific findings, trial registration, research under an IND in effect, marketing approval, warning letters, legislation, guidance, policy deliberations and this publication’s contractual and governance recommendations have different legal significance. An FDA warning letter communicates the agency’s findings in an identified matter, not a final judicial judgment. Historical alerts and reference translations must not be used as exhaustive accounts of current approvals or commencement.
This is not a systematic review of the clinical literature or an exhaustive survey of all U.S. state regulation. Clinical effectiveness, product classification, medical provision, advertising, data use, foreign-investment screening and state-specific medical, pharmacy and corporate-practice rules depend on the technology, use, entity, agreement and facts. Pending policies, proposed regimes and promulgated but uncommenced provisions are not present permissions or exemptions. Current official law and regulatory material should be rechecked before commercialisation, treatment, investment or information transfer. The governing Japanese legal text, or the authoritative text of the relevant foreign jurisdiction, should take precedence over explanatory translations, with appropriately qualified legal, clinical and technical advice obtained for specific projects.